Abstract: This invention provides porated cartilage products and methods of producing porated cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.

Abstract: Artificial tan removal compositions, methods of preparation and methods of use are provided. The tan removal compositions contain urea and are alkaline in pH. The compositions are effective at removing artificial tan from skin rapidly and in a single application. The compositions are substantially stable over long periods of time.

Abstract: The present invention relates to a synergistic hepatoprotective composition and in particular to a synergistic hepatoprotective composition having a novel combination of the phytochemicals namely curcuminoids and carotenoids such as lutein. The synergistic hepatoprotective composition is effective in promoting health more particularly in protecting normal liver function. Also provided is a novel process for manufacturing such a composition and its use in foods, beverages including alcoholic beverages and as nutraceuticals, dietary supplements and pharmaceuticals.

Abstract: A solid dosage form for injection and a method of making said dosage form wherein the dosage form has a moisture content of 5% (w/w) or less. The solid dosage form comprises a dried matrix including a first excipient and 0.01 to 50% (w/w) or more than 50% and up to 80% (w/w) of a therapeutic peptide; and one or more additional excipients and at least 5% (w/w) of CMC, based on the total weight of the solid dosage form, wherein the dosage form has a width of 0.5 mm to 2 mm.

Abstract: An inventive cleansing composition includes at least one polysaccharide derivative selected from holosides and a non-sulfated glycosaminoglycan, the at least one polysaccharide derivative, and a blend of two or more surfactants, the blend of two or more surfactants, selected from anionic surfactants, amphoteric/zwitterionic surfactants, non-ionic surfactants. The cosmetic composition may be a single phase, water-based composition, and is free or essentially free of silicones.

Abstract: A system for the transdermal delivery of drugs, vitamins, or micronutrients over a time interval of up to one month. The transdermal delivery system employs a plurality of varying diameter bioactive glass capsules configured to react with water in the bloodstream to break down and release a contained dose of a drug, vitamin, or other micronutrients. The bioactive glass capsules are microscopic and able to be absorbed through the skin. An adhesive bandage is adhered to the skin via an adhesive layer. A concealed membrane is positioned centrally on an inner surface of the adhesive bandage and separated by a barrier layer. The bioactive glass capsules are housed within the concealed membrane until the patch is placed on the skin allowing them to absorb through the skin to deliver up to a month's dose of the drug, vitamin, or other micronutrients into the bloodstream.

Abstract: A composition including a synergistic combination of a vitamin D3 or a derivative or precursor thereof and hyaluronic acid or derivate thereof encapsulated in a lipid based colloidal carrier system (preferably lipid based vesicles such as liposomes, niosomes, tranferosomes) and topical formulations thereof, as well as their use in the prevention and/or treatment of inflamed skin and mucous membrane, especially in the prevention and/or treatment of skin photodamage, in particular in the prevention and/or treatment of skin erythema (skin inflammation) and actinic keratosis, as well non melanoma skin cancer.

Abstract: Devices, groups of devices, kits, and methods for using the devices and kits to administer a local anesthetic to a port site to numb the site prior to infusion or blood draw are described. The devices contain a flexible material with an adhesive coating on one side and a compartment for containing the medication. The device can be pre-filled or a fillable device. In fillable devices, the local anesthetic is transferred from a container into the compartment of the device via the inlet after the device is applied to the patient's skin. In pre-filled devices, the local anesthetic is inside the compartment and is covered with a removable layer to keep it sterile until use. When applied to the patient's skin, the device conforms to the surface of the patient's skin forming a seal keeping the medication in contact with port site.

Abstract: The present invention is directed to an absorbable hemostatic patch that utilizes a biocompatible fibrous, fabric substrate that is melt-blown and napped or loosened at the surface, with the substrate having a low-profile, high flexibility, strength and porosity that is suitable for coating cross-linkable active molecules and ultimately effective for use as a hemostat in situations of problematic bleeding.

Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in fasted state is 400 ng/ml or less, is disclosed.

Abstract: Use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, in which the inner phase comprises the additive and an active agent dissolved therein, the additive has a higher affinity to water than to the active agent, for the control of the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, with the maintenance of the permeation rate proportional to the amount of active agent in the biphasic layer.

Abstract: A transdermal drug delivery device is disclosed. Over an extended wear period, the device causes cumulative moderate irritation plus significant irritation of less than 5% and/or achieves a meaningful degree of detachment over a seven day period of less than 20%.

Abstract: The invention provides a particle consisting essentially of micronized ESM and having a mean particle diameter of less than 100 ?m for use in promoting the healing of a chronic wound at risk of, or in which there is, (i) an inappropriate level of matrix-metalloproteinase (MMP) activity against extracellular matrix (ECM) proteins and/or peptide growth or differentiation factors, and/or (ii) an excessive inflammatory response. The invention further provides pharmaceutical compositions, wound dressings and implantable medical devices comprising the micronized ESM-containing particles for use in said treatments. The invention still further provides methods for manufacturing the micronized ESM-containing particles and the compositions, dressings and implantable medical devices comprising the same.

Abstract: A composite material for rapid blood clotting and its preparation method are provided. The composite material includes the following raw materials in parts by weight: 8˜20 parts of chitosan, 7˜14 parts of salicylaldehyde, 8˜16 parts of 2-aminoisonicotinic acid, 1.5˜3.5 parts of ferrous sulfate, 3˜5 parts of dopa, and 10˜15 parts of disodium hydrogen phosphate. The composite material for rapid blood clotting has good stability, high biological safety, significant effects on blood clotting, simple process, and easy industrial production.

Abstract: To provide a liquid medical material maintaining a colloid in a more sol form than a solid at normal temperature, having a higher function as a wound dressing material and a hemostatic material than fibrin glue, and being able to be produced safely and inexpensively. A gelatin aqueous solution including calcium at a concentration of 0.2 M or more and 1.0 M or less, and having a concentration of 5% by weight or more and 40% by weight or less, an average molecular weight of 80,000 or more and 120,000 or less, and a molecular weight distribution of 20,000 or more and 300,000 or less, and transglutaminase inducing crosslinking of the gelatin, are included. It is preferable that the calcium has a concentration of 0.2 M or more and 0.7 M or less, the gelatin has a bloom of 160 or more and 250 or less, and the transglutaminase has activity per unit of 36 U/ml to 400 U/ml.

Abstract: A composition for mitigating, inhibiting, ameliorating and/or eliminating phytoplankton growth in a waterbody, the composition comprising an active ingredient at concentration of 80.0-99.5% (w/w) of the composition and a coating material at concentration of 0.5-20% (w/w) of the composition; wherein the critical surface tension of the composition is between 15-60 dyn/cm and wherein the relative density of the composition, prior to being submerged in water, is above 1 g/cm3.

Abstract: Disclosed herein are particles of at least 95% by weight of a glucocorticoid that have a specific surface area of at least 10 m2/g, methods for making, such particles, and methods for their use as therapeutics. Also disclosed herein are particles of at least 95% by weight of an indolinone that have a specific surface area of at least 10 m2/g, methods for making such particles, and methods for-their use as therapeutics.

Abstract: The reinforced porous collagen sheet includes a porous collagen sheet having Trigoneila stellata extract (TSE) and honey propolis (HP) incorporated therein. The porous collagen sheet can have various pore sizes and strong interconnectivity. The porous collagen sheets may have large pores, ranging in size from about 150 ?m to about 500 ?m.

Abstract: A benefit agent delivery system whereby benefit agents can be released over a period of time and/or a variety of different benefit agents can be delivered from the same system and/or different concentrations of benefit agents can be delivered from the same system. The benefit agent delivery system includes a plurality of microcells, wherein the microcells are filled with a formulation comprising a benefit agent and an organic solvent. The microcells include an opening, and the opening is spanned by a porous diffusion layer. Different microcells may be loaded with different benefit agents, thereby providing a mechanism to deliver different, complimentary, or incompatible benefit agents.

Abstract: The present disclosure provides a foam nasal dressing for topically administering an active agent to a nasal cavity and for absorbing fluid discharge. The foam nasal dressing comprises a foamed core portion and a foamed shell portion arranged such that the foamed core portion is at least partially disposed within the foamed shell portion. The foamed shell portion has a porosity of greater than 80% and comprises a first phase-separated polymer and an active agent. The foamed core portion comprises a second phase-separated polymer with the first and second phase-separated polymers being the same or different. The present disclosure also provides a method of forming the foam nasal dressing.